{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:41Z","timestamp":1791919661362,"version":"4.3.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sorafenib (Sor) is the only approved multikinase inhibitor indicated for the treatment of HCC. Previous studies have shown that amygdalin (Amy) possesses anticancer activities against several cancer cell lines; we suggested that these compounds might disrupt AMPK\/mTOR and BCL-2. Therefore, the current study used integrated in vitro and <jats:italic>in silico<\/jats:italic> approaches to figure out Amy and Sor\u2019s possible synergistic activity in targeting AMPK\/mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death in HepG2 cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Notably, Amy demonstrated exceptional cytotoxic selectivity against HepG2 cells in comparison to normal WI-38 cells (IC<jats:sub>50<\/jats:sub>\u2009=\u20095.21\u00a0mg\/ml; 141.25\u00a0mg\/ml), respectively. In contrast, WI-38 cells were far more sensitive to the toxicity of Sor. A substantial synergistic interaction between Amy and Sor was observed (CI<jats:sub>50<\/jats:sub>\u2009=\u20090.56), which was connected to cell cycle arrest at the S and G2\/M stages and increased apoptosis and potential necroptosis. Amy and Sor cotreatment resulted in the highest glutathione levels and induction of pro-autophagic genes AMPK, HGMB1, ATG5, Beclin 1, and LC3, suppressed the mTOR and BCL2 anti-apoptotic gene. Finally, the docking studies proposed that Amy binds to the active site of the AMPK enzyme, thus inhibiting its activity. This inhibition of AMPK ultimately leads to inhibition of mTOR and thus induces apoptosis in the HepG2 cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although more in vivo research using animal models is needed to confirm the findings, our findings contribute to the evidence supporting Amy\u2019s potential anticancer effectiveness as an alternative therapeutic option for HCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-023-04142-1","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T09:03:06Z","timestamp":1695114186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK \/mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death"],"prefix":"10.1186","volume":"23","author":[{"given":"Tarek","family":"El-Sewedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-8432","authenticated-orcid":false,"given":"Afrah Fatthi","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro E.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa M.","family":"Elbaioumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"El-Far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha Nawaf","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-4297","authenticated-orcid":false,"given":"Alaa","family":"Elmetwalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"4142_CR1","doi-asserted-by":"crossref","unstructured":"Loesch R et al. Deleting the \u03b2-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. J Hepatol (2022).","DOI":"10.1101\/2021.07.04.450836"},{"key":"4142_CR2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/hep4.1850","volume":"6","author":"Q Chen","year":"2022","unstructured":"Chen Q, et al. Molecular imaging of tumor microenvironment to assess the effects of locoregional treatment for hepatocellular carcinoma. Hepatol Commun. 2022;6:652\u201364.","journal-title":"Hepatol Commun"},{"key":"4142_CR3","doi-asserted-by":"crossref","unstructured":"Reinders MTM et al. Safety and efficacy of holmium-166 radioembolization in hepatocellular carcinoma\u2013the HEPAR primary study. J Nucl Med (2022).","DOI":"10.2967\/jnumed.122.263823"},{"key":"4142_CR4","first-page":"1","volume":"4","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, et al. A systems biology-based investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma. Sci Rep. 2014;4:1\u201310.","journal-title":"Sci Rep"},{"key":"4142_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3945\/an.111.001206","volume":"2","author":"SA Ross","year":"2011","unstructured":"Ross SA, Davis CD. MicroRNA, nutrition, and cancer prevention. Adv Nutr. 2011;2:472\u201385.","journal-title":"Adv Nutr"},{"key":"4142_CR6","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3390\/ijms19082413","volume":"19","author":"T Sasahira","year":"2018","unstructured":"Sasahira T, Kirita T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma. Int J Mol Sci. 2018;19:2413.","journal-title":"Int J Mol Sci"},{"key":"4142_CR7","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1002\/cam4.2327","volume":"8","author":"J Wang","year":"2019","unstructured":"Wang J, Li D, Cang H, Guo B. Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019;8:4709\u201321.","journal-title":"Cancer Med"},{"key":"4142_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/hep.22704","volume":"49","author":"L Mishra","year":"2009","unstructured":"Mishra L, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49:318\u201329.","journal-title":"Hepatology"},{"key":"4142_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.","journal-title":"Signal Transduct Target Ther"},{"key":"4142_CR10","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res. 2020;152:104609.","journal-title":"Pharmacol Res"},{"key":"4142_CR11","doi-asserted-by":"crossref","unstructured":"Owusu-Brackett N, Shariati M, Meric-Bernstam F. Role of pi3k\/akt\/mtor in cancer signaling. in Predictive Biomarkers in Oncology 263\u2013270 (Springer, 2019).","DOI":"10.1007\/978-3-319-95228-4_20"},{"key":"4142_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"4142_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.26323","volume":"58","author":"M Bhat","year":"2013","unstructured":"Bhat M, Sonenberg N, Gores GJ. The mTOR pathway in hepatic malignancies. Hepatology. 2013;58:810\u20138.","journal-title":"Hepatology"},{"key":"4142_CR14","doi-asserted-by":"publisher","first-page":"6837","DOI":"10.2147\/OTT.S259873","volume":"13","author":"R Chen","year":"2020","unstructured":"Chen R, et al. The role of methyltransferase NSD2 as a potential oncogene in human solid tumors. Onco Targets Ther. 2020;13:6837.","journal-title":"Onco Targets Ther"},{"key":"4142_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","volume":"109","author":"V Asati","year":"2016","unstructured":"Asati V, Mahapatra DK, Bharti SK. PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314\u201341.","journal-title":"Eur J Med Chem"},{"key":"4142_CR16","doi-asserted-by":"crossref","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Seminars in Cancer Biology (Elsevier, 2021).","DOI":"10.1016\/j.semcancer.2021.06.019"},{"key":"4142_CR17","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/ijms21041266","volume":"21","author":"G Ferr\u00edn","year":"2020","unstructured":"Ferr\u00edn G, Guerrero M, Amado V, Rodr\u00edguez-Per\u00e1lvarez M. De la Mata, M. activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci. 2020;21:1266.","journal-title":"Int J Mol Sci"},{"key":"4142_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.18632\/oncotarget.659","volume":"3","author":"JA McCubrey","year":"2012","unstructured":"McCubrey JA, et al. Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012;3:1068.","journal-title":"Oncotarget"},{"key":"4142_CR19","doi-asserted-by":"publisher","first-page":"105604","DOI":"10.1016\/j.jsbmb.2020.105604","volume":"198","author":"SW Kattan","year":"2020","unstructured":"Kattan SW, et al. Molecular docking, anti-proliferative activity and induction of apoptosis in human liver cancer cells treated with androstane derivatives: implication of PI3K\/AKT\/mTOR pathway. J Steroid Biochem Mol Biol. 2020;198:105604.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"4142_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/archsurg.2007.39","volume":"143","author":"MA Zimmerman","year":"2008","unstructured":"Zimmerman MA, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143:182\u20138.","journal-title":"Arch Surg"},{"key":"4142_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1477-2574.2011.00355.x","volume":"13","author":"MP Landman","year":"2011","unstructured":"Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco\u2010regional therapy for hepatocellular carcinoma within Milan criteria? HPB. 2011;13:783\u201391.","journal-title":"HPB"},{"key":"4142_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ebiom.2017.12.014","volume":"27","author":"J Pauty","year":"2018","unstructured":"Pauty J, et al. A vascular endothelial growth factor-dependent sprouting angiogenesis assay based on an in vitro human blood vessel model for the study of anti-angiogenic drugs. EBioMedicine. 2018;27:225\u201336.","journal-title":"EBioMedicine"},{"key":"4142_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.bcp.2010.03.034","volume":"80","author":"H Huynh","year":"2010","unstructured":"Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80:550\u201360.","journal-title":"Biochem Pharmacol"},{"key":"4142_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2174\/187152011796011055","volume":"11","author":"H Huynh","year":"2011","unstructured":"Huynh H, et al. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. Anti-Cancer Agents Med Chem (Formerly Curr Med Chem Agents). 2011;11:560\u201375.","journal-title":"Anti-Cancer Agents Med Chem (Formerly Curr Med Chem Agents)"},{"key":"4142_CR25","doi-asserted-by":"publisher","first-page":"11837","DOI":"10.3390\/ijms222111837","volume":"22","author":"Y-K Cho","year":"2021","unstructured":"Cho Y-K, Park D-H, Jeon I-C. Medication trends for age-related macular degeneration. Int J Mol Sci. 2021;22:11837.","journal-title":"Int J Mol Sci"},{"key":"4142_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/ijms18020461","volume":"18","author":"C Randrup Hansen","year":"2017","unstructured":"Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18:461.","journal-title":"Int J Mol Sci"},{"key":"4142_CR27","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","volume":"28","author":"T Shih","year":"2006","unstructured":"Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779\u2013802.","journal-title":"Clin Ther"},{"key":"4142_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/pbc.24171","volume":"59","author":"AM Marsh","year":"2012","unstructured":"Marsh AM, Lo L, Cohen RA, Feusner JH. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. Pediatr Blood Cancer. 2012;59:939\u201340.","journal-title":"Pediatr Blood Cancer"},{"key":"4142_CR29","first-page":"1303","volume":"27","author":"N Ibrahim","year":"2012","unstructured":"Ibrahim N, Yu Y, Walsh WR, Yang J-L. Molecular targeted therapies for cancer: sorafenib monotherapy and its combination with other therapies. Oncol Rep. 2012;27:1303\u201311.","journal-title":"Oncol Rep"},{"key":"4142_CR30","doi-asserted-by":"publisher","first-page":"0","DOI":"10.21608\/blj.2021.194378","volume":"17","author":"R Ali","year":"2021","unstructured":"Ali R, et al. Is amygdalin outcomes weighing detriments of Sorafenib Treatment in female mice with kidney Injury Induced by Ehrlich Ascites Carcinoma Model? Preliminary study. Biochem Lett. 2021;17:0.","journal-title":"Biochem Lett"},{"key":"4142_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21608\/blj.2021.184392","volume":"17","author":"HM Nasser","year":"2021","unstructured":"Nasser HM, El-Naggar SA, El-Sayed Rizk ME-SR, Elmetwalli A, Salama AF. Effect of Sorafenib on Liver Biochemistry prior to vitamin B17 Coadministration in Ehrlich Ascites Carcinoma mice Model: preliminary phase study. Biochem Lett. 2021;17:40\u20139.","journal-title":"Biochem Lett"},{"key":"4142_CR32","doi-asserted-by":"crossref","unstructured":"Dowling II, Eliche CE, B., Bagasra O. Effects of Amygdalin on prostate cancer. Herbal Medicines 591\u2013609 (Elsevier, 2022).","DOI":"10.1016\/B978-0-323-90572-5.00022-6"},{"key":"4142_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.toxrep.2018.05.015","volume":"5","author":"E Kolesar","year":"2018","unstructured":"Kolesar E, et al. Assessment of rabbit spermatozoa characteristics after amygdalin and apricot seeds exposure in vivo. Toxicol Rep. 2018;5:679\u201386.","journal-title":"Toxicol Rep"},{"key":"4142_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2478\/ahem-2022-0013","volume":"76","author":"A Zieli\u0144ska","year":"2022","unstructured":"Zieli\u0144ska A, P\u0142onka-Czerw J, Nowak A, Ku\u015bmierz D. Effect of amygdalin on MCF-7, MDA-MB-231 and T-47D breast cancer cells in the in vitro study. Postepy Hig Med Dosw. 2022;76:132\u201342.","journal-title":"Postepy Hig Med Dosw"},{"key":"4142_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.phymed.2016.02.004","volume":"23","author":"RA Blaheta","year":"2016","unstructured":"Blaheta RA, Nelson K, Haferkamp A, Juengel E. Amygdalin, quackery or cure? Phytomedicine. 2016;23:367\u201376.","journal-title":"Phytomedicine"},{"key":"4142_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/01635581.2018.1508731","volume":"71","author":"MM Abboud","year":"2019","unstructured":"Abboud MM, Awaida A, Alkhateeb W, H. H., Abu-Ayyad AN. Antitumor action of amygdalin on human breast cancer cells by selective sensitization to oxidative stress. Nutr Cancer. 2019;71:483\u201390.","journal-title":"Nutr Cancer"},{"key":"4142_CR37","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1002\/cam4.2197","volume":"8","author":"J Shi","year":"2019","unstructured":"Shi J, et al. Recent updates and future perspectives about amygdalin as a potential anticancer agent: a review. Cancer Med. 2019;8:3004\u201311.","journal-title":"Cancer Med"},{"key":"4142_CR38","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.3390\/molecules26195972","volume":"26","author":"D Figurov\u00e1","year":"2021","unstructured":"Figurov\u00e1 D, et al. Inflammation, it\u2019s regulation and antiphlogistic effect of the cyanogenic glycoside amygdalin. Molecules. 2021;26:5972.","journal-title":"Molecules"},{"key":"4142_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-10517-0","volume":"12","author":"AA Attia","year":"2022","unstructured":"Attia AA, et al. Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage. Sci Rep. 2022;12:1\u20139.","journal-title":"Sci Rep"},{"key":"4142_CR40","doi-asserted-by":"crossref","unstructured":"Liu W, Jin W, Zhu S, Chen Y, Liu B. Targeting regulated cell death (RCD) with small-molecule compounds in cancer therapy: a revisited review of apoptosis, autophagy-dependent cell death and necroptosis. Drug Discov Today (2021).","DOI":"10.1016\/j.drudis.2021.10.011"},{"key":"4142_CR41","first-page":"331","volume":"13","author":"DM Chung","year":"2015","unstructured":"Chung DM, Kim JH, Kim JK. Evaluation of MTT and Trypan Blue assays for radiation-induced cell viability test in HepG2 cells. Int J Radiat Res. 2015;13:331.","journal-title":"Int J Radiat Res"},{"key":"4142_CR42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay MethodSynergy quantification method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"4142_CR43","first-page":"52","volume":"1","author":"M Patel Rajesh","year":"2011","unstructured":"Patel Rajesh M, Patel Natvar J. In vitro antioxidant activity of coumarin compounds by DPPH, Super oxide and nitric oxide free radical scavenging methods. J Adv Pharm Educ Res. 2011;1:52\u201368.","journal-title":"J Adv Pharm Educ Res"},{"key":"4142_CR44","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.freeradbiomed.2017.08.008","volume":"112","author":"D Giustarini","year":"2017","unstructured":"Giustarini D, et al. Assessment of glutathione\/glutathione disulphide ratio and S-glutathionylated proteins in human blood, solid tissues, and cultured cells. Free Radic Biol Med. 2017;112:360\u201375.","journal-title":"Free Radic Biol Med"},{"key":"4142_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ab.2016.10.021","volume":"524","author":"D Tsikas","year":"2017","unstructured":"Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. Anal Biochem. 2017;524:13\u201330.","journal-title":"Anal Biochem"},{"key":"4142_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jim.2015.04.025","volume":"423","author":"S Pietkiewicz","year":"2015","unstructured":"Pietkiewicz S, Schmidt JH, Lavrik IN. Quantification of apoptosis and necroptosis at the single cell level by a combination of Imaging Flow Cytometry with classical annexin V\/propidium iodide staining. J Immunol Methods. 2015;423:99\u2013103.","journal-title":"J Immunol Methods"},{"key":"4142_CR47","first-page":"67","volume":"3","author":"R Nunez","year":"2001","unstructured":"Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol. 2001;3:67\u201370.","journal-title":"Curr Issues Mol Biol"},{"key":"4142_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 \u2013 \u2206\u2206CT method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"4142_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000443404","volume":"25","author":"GM Cragg","year":"2016","unstructured":"Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25:41\u201359.","journal-title":"Med Princ Pract"},{"key":"4142_CR50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ajcp\/aqz126.001","volume":"152","author":"M Shedid","year":"2019","unstructured":"Shedid M, Abdelmonem M, Boraik A, Elmetwalli A, Esmael A. Role of plasma miRNA-501 expression Profile as a marker of Hepatocellular Carcinoma (HCC) Progression with Hepatitis C virus infection. Am J Clin Pathol. 2019;152:134.","journal-title":"Am J Clin Pathol"},{"key":"4142_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"key":"4142_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000342402","volume":"1","author":"M Kudo","year":"2012","unstructured":"Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver cancer. 2012;1:62\u201370.","journal-title":"Liver cancer"},{"key":"4142_CR53","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.4254\/wjh.v7.i8.1041","volume":"7","author":"S Colagrande","year":"2015","unstructured":"Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7:1041.","journal-title":"World J Hepatol"},{"key":"4142_CR54","doi-asserted-by":"publisher","first-page":"188382","DOI":"10.1016\/j.bbcan.2020.188382","volume":"1874","author":"Z Cheng","year":"2020","unstructured":"Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta (BBA)-Reviews Cancer. 2020;1874:188382.","journal-title":"Biochim Biophys Acta (BBA)-Reviews Cancer"},{"key":"4142_CR55","doi-asserted-by":"publisher","first-page":"100741","DOI":"10.1016\/j.tranon.2020.01.002","volume":"13","author":"S Wang","year":"2020","unstructured":"Wang S, et al. Inhibition of EZH2 attenuates sorafenib resistance by targeting NOTCH1 activation-dependent liver cancer stem cells via NOTCH1-related MicroRNAs in hepatocellular carcinoma. Transl Oncol. 2020;13:100741.","journal-title":"Transl Oncol"},{"key":"4142_CR56","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.7150\/jca.34374","volume":"11","author":"B Rizeq","year":"2020","unstructured":"Rizeq B, et al. The power of phytochemicals combination in cancer chemoprevention. J Cancer. 2020;11:4521.","journal-title":"J Cancer"},{"key":"4142_CR57","doi-asserted-by":"publisher","first-page":"105660","DOI":"10.1016\/j.cmpb.2020.105660","volume":"195","author":"K Al-Khafaji","year":"2020","unstructured":"Al-Khafaji K, Tok TT. Molecular dynamics simulation, free energy landscape and binding free energy computations in exploration the anti-invasive activity of amygdalin against metastasis. Comput Methods Programs Biomed. 2020;195:105660.","journal-title":"Comput Methods Programs Biomed"},{"key":"4142_CR58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21608\/blj.2021.198557","volume":"17","author":"A Elmalla","year":"2021","unstructured":"Elmalla A, Elmetwalli A, Rizk ME-S, Salama AF. The effect of vitamin B17 on Cardiomyopathy against Ehrlich Tumor Development in Female mice. Biochem Lett. 2021;17:69\u201376.","journal-title":"Biochem Lett"},{"key":"4142_CR59","doi-asserted-by":"crossref","unstructured":"Meerloo J, Van, Kaspers GJL, Cloos J. Cell sensitivity assays: the MTT assay. in Cancer cell culture 237\u2013245 (Springer, 2011).","DOI":"10.1007\/978-1-61779-080-5_20"},{"key":"4142_CR60","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4103\/jomfp.JOMFP_281_18","volume":"23","author":"D Sireesha","year":"2019","unstructured":"Sireesha D, Reddy BS, Reginald BA, Samatha M, Kamal F. Effect of amygdalin on oral cancer cell line: an in vitro study. J Oral Maxillofac Pathol JOMFP. 2019;23:104.","journal-title":"J Oral Maxillofac Pathol JOMFP"},{"key":"4142_CR61","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1007\/s11033-019-05080-3","volume":"46","author":"B Moradipoodeh","year":"2019","unstructured":"Moradipoodeh B, Jamalan M, Zeinali M, Fereidoonnezhad M, Mohammadzadeh G. In vitro and in silico anticancer activity of amygdalin on the SK-BR-3 human breast cancer cell line. Mol Biol Rep. 2019;46:6361\u201370.","journal-title":"Mol Biol Rep"},{"key":"4142_CR62","first-page":"130","volume":"26","author":"SP Choi","year":"2005","unstructured":"Choi SP, Song YK, Kim KJ, Lim HH. Amygdalin extract from armeniacae semen induces apoptosis through bax-dependent caspase-3 activation in human cervical cancer cell line ME-180. J Korean Med. 2005;26:130\u201342.","journal-title":"J Korean Med"},{"key":"4142_CR63","doi-asserted-by":"publisher","first-page":"366","DOI":"10.9734\/EJMP\/2015\/14081","volume":"5","author":"PN Nabende","year":"2015","unstructured":"Nabende PN, Karanja SM, Mwatha JK, Wachira SW. Anti-proliferative activity of Prunus africana, Warburgia stuhlmannii and Maytenus senegalensis extracts in breast and colon cancer cell lines. Eur J Med Plants. 2015;5:366.","journal-title":"Eur J Med Plants"},{"key":"4142_CR64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.sajb.2019.02.006","volume":"123","author":"T Murati","year":"2019","unstructured":"Murati T, et al. Comparative assessment of Prunus spinosa L. flower extract in non-neoplastic hepatocytes and hepatoblastoma cells. South Afr J Bot. 2019;123:36\u201342.","journal-title":"South Afr J Bot"},{"key":"4142_CR65","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.2174\/1381612033454072","volume":"9","author":"LF Tietze","year":"2003","unstructured":"Tietze LF, Feuerstein T. Enzyme and proton-activated prodrugs for a selective cancer therapy. Curr Pharm Des. 2003;9:2155\u201375.","journal-title":"Curr Pharm Des"},{"key":"4142_CR66","doi-asserted-by":"crossref","unstructured":"Roy A, Datta S, Bhatia KS, Jha P, Prasad R. Role of plant derived bioactive compounds against cancer. South Afr J Bot (2021).","DOI":"10.1016\/j.sajb.2021.10.015"},{"key":"4142_CR67","doi-asserted-by":"publisher","first-page":"119961","DOI":"10.1016\/j.lfs.2021.119961","volume":"285","author":"AM Mamdouh","year":"2021","unstructured":"Mamdouh AM, Khodeer DM, Tantawy MA, Moustafa YM. In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma. Life Sci. 2021;285:119961.","journal-title":"Life Sci"},{"key":"4142_CR68","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2174\/1874467213666200810141251","volume":"14","author":"B Mosayyebi","year":"2021","unstructured":"Mosayyebi B, Mohammadi L, Kalantary-Charvadeh A, Rahmati M. Amygdalin decreases Adhesion and Migration of MDA-MB-231 and MCF-7 breast Cancer cell lines. Curr Mol Pharmacol. 2021;14:667\u201375.","journal-title":"Curr Mol Pharmacol"},{"key":"4142_CR69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nnano.2011.191","volume":"7","author":"JA Kim","year":"2012","unstructured":"Kim JA, \u00c5berg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol. 2012;7:62\u20138.","journal-title":"Nat Nanotechnol"},{"key":"4142_CR70","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.3390\/cancers12113150","volume":"12","author":"SD Markowitsch","year":"2020","unstructured":"Markowitsch SD, et al. Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis. Cancers (Basel). 2020;12:3150.","journal-title":"Cancers (Basel)"},{"key":"4142_CR71","doi-asserted-by":"crossref","unstructured":"Cook A, Siddiqi SA, Phytochemicals. Current Understandings of the Modern Therapeutic Approaches for Hepatocellular Carcinoma. in Phytochemicals Targeting Tumor Microenvironment in Gastrointestinal Cancers 303\u2013329 (Springer, 2020).","DOI":"10.1007\/978-3-030-48405-7_14"},{"key":"4142_CR72","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1016\/j.csbj.2021.07.038","volume":"19","author":"Y Wang","year":"2021","unstructured":"Wang Y, Kanneganti T-D. From pyroptosis, apoptosis and necroptosis to PANoptosis: a mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J. 2021;19:4641\u201357.","journal-title":"Comput Struct Biotechnol J"},{"key":"4142_CR73","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s11033-020-05286-w","volume":"47","author":"F Aamazadeh","year":"2020","unstructured":"Aamazadeh F, Ostadrahimi A, Rahbar Saadat Y, Barar J. Bitter apricot ethanolic extract induces apoptosis through increasing expression of Bax\/Bcl-2 ratio and caspase-3 in PANC-1 pancreatic cancer cells. Mol Biol Rep. 2020;47:1895\u2013904.","journal-title":"Mol Biol Rep"},{"key":"4142_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2724-5","volume":"11","author":"M Noguchi","year":"2020","unstructured":"Noguchi M, et al. Autophagy as a modulator of cell death machinery. Cell Death Dis. 2020;11:1\u201312.","journal-title":"Cell Death Dis"},{"key":"4142_CR75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"key":"4142_CR76","doi-asserted-by":"publisher","first-page":"7994","DOI":"10.3390\/ijms21217994","volume":"21","author":"F Juszczak","year":"2020","unstructured":"Juszczak F, Caron N, Mathew AV, Decl\u00e8ves A-E. Critical role for AMPK in metabolic disease-induced chronic kidney disease. Int J Mol Sci. 2020;21:7994.","journal-title":"Int J Mol Sci"},{"key":"4142_CR77","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/15548627.2018.1505155","volume":"15","author":"J Jia","year":"2019","unstructured":"Jia J, et al. Galectins control MTOR and AMPK in response to lysosomal damage to induce autophagy. Autophagy. 2019;15:169\u201371.","journal-title":"Autophagy"},{"key":"4142_CR78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/cells8020190","volume":"8","author":"C Simioni","year":"2019","unstructured":"Simioni C, Martelli AM, Zauli G, Melloni E, Neri LM. Targeting mTOR in acute lymphoblastic leukemia. Cells. 2019;8:190.","journal-title":"Cells"},{"key":"4142_CR79","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.jhep.2020.06.027","volume":"73","author":"P Dong","year":"2020","unstructured":"Dong P, et al. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1\/TSC2 association in hepatocellular carcinoma. J Hepatol. 2020;73:1446\u201359.","journal-title":"J Hepatol"},{"key":"4142_CR80","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jhep.2020.07.036","volume":"74","author":"Y-D Luo","year":"2021","unstructured":"Luo Y-D, et al. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma. J Hepatol. 2021;74:96\u2013108.","journal-title":"J Hepatol"},{"key":"4142_CR81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/MCB.06159-11","volume":"32","author":"A Sebastian","year":"2012","unstructured":"Sebastian A, Sebastian SLA, W., Bj\u00f6rn S. Role of AMPK-mTOR-Ulk1\/2 in the regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks. Mol Cell Biol. 2012;32:2\u201311.","journal-title":"Mol Cell Biol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-023-04142-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T11:04:42Z","timestamp":1700478282000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-023-04142-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4142"],"URL":"https:\/\/doi.org\/10.1186\/s12906-023-04142-1","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}